Cargando…
Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases
Osteosarcoma is the main malignant primary bone tumor in children and adolescents for whom the prognosis remains poor, especially when metastases are present at diagnosis. Because we recently demonstrated that TGF-β/Smad cascade plays a crucial role in osteosarcoma metastatic progression, we investi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546476/ https://www.ncbi.nlm.nih.gov/pubmed/26015407 |
_version_ | 1782386937698451456 |
---|---|
author | Lamora, Audrey Mullard, Mathilde Amiaud, Jérôme Brion, Régis Heymann, Dominique Redini, Françoise Verrecchia, Franck |
author_facet | Lamora, Audrey Mullard, Mathilde Amiaud, Jérôme Brion, Régis Heymann, Dominique Redini, Françoise Verrecchia, Franck |
author_sort | Lamora, Audrey |
collection | PubMed |
description | Osteosarcoma is the main malignant primary bone tumor in children and adolescents for whom the prognosis remains poor, especially when metastases are present at diagnosis. Because we recently demonstrated that TGF-β/Smad cascade plays a crucial role in osteosarcoma metastatic progression, we investigated the effect of halofuginone, identified as an inhibitor of the TGF-β/Smad3 cascade, on osteosarcoma progression. A preclinical model of osteosarcoma was used to evaluate the impact of halofuginone on tumor growth, tumor microenvironment and metastasis development. In vivo experiments showed that halofuginone reduces primary tumor growth and lung metastases development. In vitro experiments demonstrated that halofuginone decreases cell viability mainly by its ability to induce caspase-3 dependent cell apoptosis. Moreover, halofuginone inhibits the TGF-β/Smad3 cascade and the response of TGF-β key targets involved in the metastases dissemination process such as MMP-2. In addition, halofuginone treatment affects the “vicious cycle” established between tumor and bone cells, and therefore the tumor-associated bone osteolysis. Together, these results demonstrate that halofuginone decreased primary osteosarcoma development and associated lung metastases by targeting both the tumor cells and the tumor microenvironment. Using halofuginone may be a promising therapeutic strategy against tumor progression of osteosarcoma specifically against lung metastases dissemination. |
format | Online Article Text |
id | pubmed-4546476 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-45464762015-08-27 Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases Lamora, Audrey Mullard, Mathilde Amiaud, Jérôme Brion, Régis Heymann, Dominique Redini, Françoise Verrecchia, Franck Oncotarget Research Paper Osteosarcoma is the main malignant primary bone tumor in children and adolescents for whom the prognosis remains poor, especially when metastases are present at diagnosis. Because we recently demonstrated that TGF-β/Smad cascade plays a crucial role in osteosarcoma metastatic progression, we investigated the effect of halofuginone, identified as an inhibitor of the TGF-β/Smad3 cascade, on osteosarcoma progression. A preclinical model of osteosarcoma was used to evaluate the impact of halofuginone on tumor growth, tumor microenvironment and metastasis development. In vivo experiments showed that halofuginone reduces primary tumor growth and lung metastases development. In vitro experiments demonstrated that halofuginone decreases cell viability mainly by its ability to induce caspase-3 dependent cell apoptosis. Moreover, halofuginone inhibits the TGF-β/Smad3 cascade and the response of TGF-β key targets involved in the metastases dissemination process such as MMP-2. In addition, halofuginone treatment affects the “vicious cycle” established between tumor and bone cells, and therefore the tumor-associated bone osteolysis. Together, these results demonstrate that halofuginone decreased primary osteosarcoma development and associated lung metastases by targeting both the tumor cells and the tumor microenvironment. Using halofuginone may be a promising therapeutic strategy against tumor progression of osteosarcoma specifically against lung metastases dissemination. Impact Journals LLC 2015-05-07 /pmc/articles/PMC4546476/ /pubmed/26015407 Text en Copyright: © 2015 Lamora et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Lamora, Audrey Mullard, Mathilde Amiaud, Jérôme Brion, Régis Heymann, Dominique Redini, Françoise Verrecchia, Franck Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases |
title | Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases |
title_full | Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases |
title_fullStr | Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases |
title_full_unstemmed | Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases |
title_short | Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases |
title_sort | anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546476/ https://www.ncbi.nlm.nih.gov/pubmed/26015407 |
work_keys_str_mv | AT lamoraaudrey anticanceractivityofhalofuginoneinapreclinicalmodelofosteosarcomainhibitionoftumorgrowthandlungmetastases AT mullardmathilde anticanceractivityofhalofuginoneinapreclinicalmodelofosteosarcomainhibitionoftumorgrowthandlungmetastases AT amiaudjerome anticanceractivityofhalofuginoneinapreclinicalmodelofosteosarcomainhibitionoftumorgrowthandlungmetastases AT brionregis anticanceractivityofhalofuginoneinapreclinicalmodelofosteosarcomainhibitionoftumorgrowthandlungmetastases AT heymanndominique anticanceractivityofhalofuginoneinapreclinicalmodelofosteosarcomainhibitionoftumorgrowthandlungmetastases AT redinifrancoise anticanceractivityofhalofuginoneinapreclinicalmodelofosteosarcomainhibitionoftumorgrowthandlungmetastases AT verrecchiafranck anticanceractivityofhalofuginoneinapreclinicalmodelofosteosarcomainhibitionoftumorgrowthandlungmetastases |